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Abstract
Background: Pen c 13, identified as a 33-kDa alkaline serine protease, is a major allergen secreted by Penicillium citrinum.
Detailed knowledge about the epitopes responsible for IgE binding would help inform the diagnosis/prognosis of fungal
allergy and facilitate the rational design of hypoallergenic candidate vaccines. The goal of the present study was to
characterize the IgE epitopes of Pen c 13.
Methodology/Principal Findings: Serum samples were collected from 10 patients with mold allergy and positive Pen c 13
skin test results. IgE-binding epitopes on rPen c 13 were mapped using an enzymatic digestion and chemical cleavage
method, followed by dot-blotting and mass spectrometry. A B-cell epitope-predicting server and molecular modeling were
used to predict the residues most likely involved in IgE binding. Theoretically predicted IgE-binding regions were further
confirmed by site-directed mutagenesis assays. At least twelve different IgE-binding epitopes located throughout Pen c 13
were identified. Of these, peptides S16 (A
148–E
166) and S22 (A
243–K
274) were recognized by sera from 90% and 100% of the
patients tested, and were further confirmed by inhibition assays. Peptide S22 was selected for further analysis of IgE-binding
ability. The results of serum screening showed that the majority of IgE-binding ability resided in the C-terminus. One Pen c
13 mutant, G270A (T
261–K
274), exhibited clearly enhanced IgE reactivity, whereas another, K274A, exhibited dramatically
reduced IgE reactivity.
Conclusions/Significance: Experimental analyses confirmed in silico-predicted residues involved in an important antigenic
region of Pen c 13. The G270A mutant of Pen c 13 has the potential to serve as an additional tool for the diagnosis/
prognosis of mold allergy, and the K274A mutant, as a hypoallergenic form of the epitope, may provide a framework for the
design and development of a safe and efficient therapeutic strategy for treating human allergic diseases.
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Introduction
Fungi are ubiquitous in our environment, and many have been
identified as causative factors in IgE-mediated allergy. Among the
fungi associated with allergic disorders, Penicillium sp. is one of the
most frequently encountered species [1–4]. Previous studies
identified the major allergen Pen c 13, a highly prevalent allergen
secreted by Penicillium citrinum among patients with mold allergy
[5], as a 33-kDa alkaline serine protease, and showed that it might
directly contribute to sensitization and is associated with the
development of asthma [6–9]. These effects probably result from
the pathophysiological changes in the lung microenvironment, the
expression of thymic stromal lymphopoietin, and the migration of
antigen-presenting cells to the draining lymph node under the
influence of protease [10–12].
Understanding of IgE-binding epitopes on allergens should help
elucidate allergen-antibody interactions and may contribute to the
development of more effective immunotherapeutic strategies. It
has been demonstrated that immunotherapy induces strong
allergen-specific IgG responses and that protective IgG antibodies
are important for the success of allergen-specific immunotherapy
[13–17]. The effectiveness of recently developed genetically
engineered and synthetic allergen derivatives that have been
modified to reduce their allergenic activity demonstrates the
potential use of specific epitopes in immunotherapeutic approach-
es to allergic disease [18–21].
Among the strategies for identifying allergen epitopes are
fragmentation of allergens, either enzymatically [3,22] or synthet-
ically [23,24]; phage display [25,26]; and various recombinant
technologies [27–29]. Epitopes might be composed of sequential
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quential residues from segments of the chain brought together by
the folded conformation of the protein (conformational epitopes)
[30,31]. Many epitope-mapping studies of different allergens have
shown that small linear epitopes bind specifically to IgE antibodies
of allergic patients; moreover, the IgE-binding capacity of these
allergens could be abolished by single amino acid mutations within
each epitope [26,27,32–34]. Furthermore, the identification of
specific residues involved in IgE antibody binding can be sped up
using computer programs that predict B-cell epitopes [35–39].
Pharmacological agents have been the mainstay of allergy
symptom management, but allergen-specific immunotherapy is the
only long-lasting, allergen-specific approach for treating type I
allergy and preventing its progression to severe disease manifes-
tations [40–43]. An important element in the implementation of
specific immunotherapy is developing a clearer understanding of
the immunogenicity of allergen derivatives.
In the present study, we mapped the IgE-binding epitopes on
recombinant Pen c 13 (rPen c 13) using enzymatic digestion and
chemical cleavage methods, followed by dot-blotting and mass
spectrometry. A concentration-response inhibition assay was
performed to provide evidence of IgE binding. We also integrated
results from a B-cell epitope-predicting server and molecular
modeling to minimize the experimental validation process.
Subsequent site-directed mutagenesis of the residues involved in
the major epitope, S22, led to the identification of amino acids that
are important for allergen-IgE interactions. Identification of
immunodominant regions of Pen c 13 may facilitate the
development of specific peptide-based diagnostics and possibly
lead to therapies for mold allergy.
Materials and Methods
Patients’ sera
Informed consent was obtained from all patients and volunteers.
Our study was approved by the Ethics Committee of the National
Taiwan University Hospital. Sera from 80 patients with mold
allergy and control sera from 30 healthy volunteers were used in
this study. Sera were collected at the National Taiwan University
Hospital (Taipei, Taiwan) and stored in aliquots at 280uC until
use. The allergic response was confirmed by clinical history and
diagnosis, and characterized by measuring specific IgE reactivity
using the ImmunoCAPH system (Thermo Fisher Scientific,
Uppsala, Sweden). Mold-allergic patients were initially included
on the basis of an ImmunoCAP score for the crude extract of
Penicillium notatum recognized by human IgE antibodies$class 2
(0.70 kU/l). Among these patients a total of 10 individuals who
had a positive skin prick test (Method S1) response to Pen c 13
were selected to detect IgE-binding epitopes within Pen c 13.
Purification of His-tagged rPen c 13
rPen c 13 was purified as described previously [6]. Briefly, the
cDNA encoding mature Pen c 13 was obtained from a P. citrinum
DNA library by polymerase chain reaction (PCR), and the
amplified fragment was ligated into the vector pQE 30 (Qiagen,
Chatsworth, CA, USA) to generate an expression plasmid for N-
terminally His6-tagged Pen c 13 (pQE-30/Pen c 13), which was
then used to transform E. coli M15 cells (Qiagen). Cultures of
transformed cells were grown to an OD600 value of 0.6, induced
with 1 mM isopropyl-b-D-thio-galactoside (IPTG; Sigma-Al-
drich), and harvested after 2 h. The His-tagged rPen c 13, isolated
as inclusion bodies, was bound to a Ni
2+-chelate affinity column,
washed with binding buffer (20 mM Tris-HCl [pH 7.9], 0.5 M
NaCl, 8 M urea, and 5 mM imidazole), and then eluted with
elution buffer (20 mM Tris-HCl [pH 7.9], 0.5 M NaCl, 8 M urea,
and 60 mM imidazole). Finally urea was removed by sequential
dialysis with reducing urea concentrations from 8 M to 4 M, 2 M,
1 M, and 0 M against phosphate-buffered saline (PBS). The
dialyzed rPen c 13 was concentrated using the concentrators with
10 kDa cut-off membrane (Amicon Ultra, Millipore). Protein
concentrations were determined using a bicinchonic acid protein
assay reagent kit (Pierce, Rockford, IL, USA) using BSA as the
standard. The purity of rPen c 13 was verified by Coomassie
Brilliant Blue staining after SDS-PAGE and mass spectrometric
analysis.
Specific IgE quantification
The detection of specific IgE antibodies reactive with Pen c 13
was examined by enzyme-linked immunosorbent assay (ELISA)
using sera from 80 patients and 30 healthy controls. Microtiter
plates (Costar Inc., Cambridge, USA) were coated with rPen c 13
by incubating with a 0.5-mg/ml solution of rPen c 13 in PBS. Each
serum sample was serially diluted in PBS/0.1% Tween-20 and
added to plates, which were then incubated for overnight at 4uC.
Bound IgE was detected by incubating sequentially with alkaline
phosphatase-labeled anti-human IgE antibodies (Biosource Inter-
national, Camarillo, CA, USA) and a p-nitrophenyl phosphate
substrate. Plates were allowed to stand in the dark for 30 min
before reading at 405 nm. The cutoff was determined as two times
the mean of the 30 controls. To adjust for inter-plate variability,
normalized ELISA values were calculated by dividing the optical
density (OD) of the test samples by the mean OD of the reference
sera on each plate.
Peptide purification and identification
Pen c 13 peptides were obtained through enzymatic and
chemical cleavage. rPen c 13 was digested overnight at 37uC with
lysyl endopeptidase (EC 3.4.21.50), trypsin (EC 3.4.21.4),
chymotrypsin (EC 3.4.21.1), or Glu-C endopeptidase (EC
3.4.21.19) at an enzyme/substrate ratio of 1:50. Lysyl endopep-
tidase, trypsin, and chymotrypsin digestions were carried out in
0.1 M pyridine/acetate/collidine (pH 8.2), and Glu-C endopep-
tidase digestions were performed in 0.1 mM calcium chloride and
0.1 M pyridine/acetate (pH 6.5). The resulting peptides were
fractionated by reversed-phase high-performance liquid chroma-
tography (HPLC) on a Beckman ODS (C18) column (300 A ˚,
4.66250 mm) using a linear gradient of 0–44% acetonitrile in
0.06% trifluoroacetic acid and a flow rate of 1 ml/min. Cyanogen
bromide (CNBr) cleavage was performed at 37uC for 24 h in 70%
formic acid with a 100-fold molar excess of CNBr over methionine
residues. After cleavage, the fragments were separated by HPLC
on a YMC-Pack C4 column (300 A ˚, 4.66150 mm) using the same
elution system as for the Beckman column. Peptide elution was
monitored at 220 nm, and all fractions were collected and
analyzed for peptide mass and purity using a Procise ABI 494
protein sequencer (Applied Biosystems, Foster City, CA, USA) and
a QSTAR XL mass spectrometer (Applied Biosystems).
Dot-blot immunoassays
Approximately 30 pmol each of lysyl endopeptidase-, trypsin-,
chymotrypsin-, Glu-C endopeptidase-, and CNBr-cleaved pep-
tides from rPen c 13 was spotted onto a polyvinylidene fluoride
(PVDF) membrane. A total of 24 peptides covering most of the
Pen c 13 sequence were screened for their ability to bind human
IgE in individual serum samples from allergic subjects. Bound
antibodies were detected using alkaline phosphatase-conjugated
goat anti-human IgE (Biosource) and the CDP-Star detection
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tions.
IgE-binding inhibition assay
To evaluate the major epitopes S16 and S22, using three
individual patient sera (patient 1, 7, and 10), with a high, medium
and low ranges of the ELISA OD values were previously
incubated overnight at 4uC with different concentrations of S16,
S22, or both. For inhibition control, a pool of sera from the 10
patients was previously incubated overnight at 4uC with different
concentrations of rPen c 13 as a positive control or albumin as the
negative one. Microtiter plates (Costar Inc., Cambridge, USA)
were coated with rPen c 13 by incubating for overnight at 4uC
with 100 mlo fa5 - mg/ml solution of rPen c 13 in PBS, then
incubated for overnight at 4uC with aliquots of separate sera
(diluted 1:10) that had previously been incubated with different
concentrations of peptides or proteins as mentioned above. The
amount of specific IgE bound to the wells was determined as
described above.
Computational matching of epitopes
To assist in the identification of potential residues that are
critical in IgE binding, we utilized an epitope conservancy analysis
tool. This tool was implemented as a component of the Immune
Epitope Database and Analysis Resources (IEDB) [39] and was
used for predicting B-cell epitopes. Amino acid property scales for
predicting antigenic determinants were developed based on
Bepipred Linear Epitope Prediction (BepiPred), which predicts
the location of linear B-cell epitopes using a combination of a
hidden Markov model and a propensity scale method [35].
Molecular modeling of Pen c 13
Pen c 13 was modeled based on the structure of the alkaline
serine protease from Lecanicillium psalliotae, Ver112 (Protein Data
Bank code 3F7M), which is the mostly closely related to Pen c 13
(highest BLAST score value) in the structure database [44]. To
further examine the Pen c 13 structure, we generated a three-
dimensional (3D) model structure using the SWISS-MODEL
structure homology-modeling server [45]. The images were
obtained and rendered with PyMOL software.
Expression and purification of the GST fusion rPen c 13
peptides, (A
243–K
274), (A
243–A
260) and (T
261–K
274)
The region of the Pen c 13 targeted for (A
243–K
274), (A
243–A
260)
and (T
261–K
274), is amplified using pQE-30/Pen c 13 as a template
and the PCR with oligonucleotide primers (F243 BamHI, 59-
GGATCCGCTCTCGAGGGCGTGTCAGCT-39; R274 EcoRI,
59-GAATTCTTACTTGCTTGTAGTGCCAGA-39; R260 EcoRI,
59-GAATTCTTAAGCGAGCTGGACAATACG-39;F261BamHI,
59-GGATCCACCTCGTCAATCTCTAGGGCT-39)d e s i g n e d
specifically for amplification of the piece of cDNA of interest.
Incorporating restriction sites into the primers facilitates subcloning
into the multiple cloning site of the pGEX-2T vector. The PCR
products were gel-purified and then ligated into the pGEX-2T
expression vector (GE Healthcare) at BamHI and EcoRI sites. The
fidelity of the cloned sequence was confirmed by DNA sequencing.
For production of recombinant proteins, all plasmids were
transformed into Escherichia coli strain BL-21 (DE3) (Stratagene, La
Figure 1. IgE-reactivity of human sera against rPen c 13. The
binding of rPen c 13 to serum IgE from 80 patients allergic to molds and
30 nonatopic subjects was tested by ELISA. Each data point represents
an individual patient or healthy control. The horizontal dotted line
shows the cutoff of the reaction, defined as two times the mean value
of the healthy control group. Percentage values represent the overall
frequency of positive responders among mold-allergic patients. The
mean values are indicated by horizontal bars. Significance for unpaired
comparisons of mean values between two groups was calculated using
a two-tailed Mann-Whitney U test. The significance level was specified
as a=0.05. *P,0.0001.
doi:10.1371/journal.pone.0034627.g001
Table 1. Characterization of sera from patients with positive IgE binding to rPen c 13.
Patient No. Sex
Age
(y) Symptoms
Serum total
IgE (kU/L) Pen c 13 ELISA (OD) ImmunoCAP score
1 M 66 AS 951 1.45 +3
2 M 56 AS,AR 1565 1.28 +2
3 M 41 AS,UR 411 1.22 +2
4 M 24 AR 120 1.19 +2
5M 2 2 A D .2000 1.16 +4
6 M 28 AS,AR,AD 782 1.07 +2
7 F 22 AR,AD .2000 1.04 +2
8 F 10 AR,AD .2000 1.01 +3
9 M 33 AS,AR,AD .2000 0.96 +3
10 M 20 AS,AR,AD .2000 0.94 +3
AD, atopic dermatitis; AR, atopic rhinitis; AS, asthma; UR, urticaria.
doi:10.1371/journal.pone.0034627.t001
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value of 0.6, induced with 1 mM IPTG, and harvested after 4 h.
Cells were resuspended in binding buffer (PBS, pH 7.4, containing
1% Triton X-100) and sonicated on ice for 5 min, after which the
suspension was centrifuged and the supernatant was loaded onto a
Glutathione Sepharose 4 Fast Flow column (GE Healthcare) pre-
equilibrated in binding buffer. After adsorption, the non-bound
material was removed by washing with binding buffer, and bound
protein was eluted using elution buffer (50 mM Tris/HCl, pH 8.0,
containing 10 mM reduced glutathione). Eluted fractions were
collected and analyzed by SDS-PAGE.
Figure 2. Mapping of IgE-binding epitopes by dot-blotting. Twenty-four overlapping peptides spanning almost the entire sequence of Pen c
13 were tested for reactivity toward serum IgE from 10 mold-allergic patients (A–J) and nonatopic individual (K). The diagram on the top-left shows
the pattern of peptides on the blots.
doi:10.1371/journal.pone.0034627.g002
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The gene fragment for wild-type (WT) Pen c 13 (T
261–K
274) was
cloned into the pGEX-2T vector as described above and used as a
template for the preparation of all Pen c 13 (T
261–K
274) mutants.
These mutants were generated using the QuikChange Site-
Directed Mutagenesis kit (Stratagene, La Jolla, CA). All mutated
genes were confirmed by direct DNA sequencing. The primers
used for mutagenesis were as follows:
S269A: 59-ATCTCTAGGGCTCCCGCTGGCACTACAAG-
CAAG-39
G270A: 59-TCTAGGGCTCCCTCTGCCACTACAAG-
CAAGTAA-39
T271A: 59-AGGGCTCCCTCTGGCGCTACAAGCAAG-
TAAGAA-39
T272A: 59-GCTCCCTCTGGCACTGCAAGCAAGTAA-
GAATTC-39
S273A: 59-CCCTCTGGCACTACAGCCAAGTAAGAATT-
CATC-39
K274A: 59-TCTGGCACTACAAGCGCGTAAGAATT-
CATCGTG-39
The nucleotide sequences were obtained from GenBank
(accession no. AF084546); the mutated sites are underlined. The
nucleotide sequences of all clones were confirmed by DNA
sequencing. All GST fusion rPen c 13 (T
261–K
274) mutants were
expressed and purified as described above.
SDS-PAGE and immunoblotting with IgE
GST fusions of WT rPen c 13 (A
243–K
274), (A
243–A
260) and
(T
261–K
274), and mutants of rPen c 13 (T
261–K
274) were separated
by SDS-PAGE along with GST only (control). For specific IgE
immunodetection, resolved GST fusion peptides were transferred
to a PVDF membrane, which was then blocked with skim milk,
and incubated with serum (diluted 1:10) from mold-allergic
patients. Bound human IgE was detected using horseradish
peroxidase-conjugated goat anti-human IgE antibodies (Bio-
Source). Bands were visualized using enhanced chemilumines-
cence reagents (Millipore) and autoradiography. Densitometric
analysis was performed using the LabWorks software (UVP
BioImaging Systems, Upland, CA, USA). The relative density of
the bands normalized to loading control.
Results
Determination of Pen c 13 IgE reactivity in patient sera by
ELISA
We have previously reported that Pen c 13 is a major allergen in
mold-allergic patients [6]. To obtain sera contained higher specific
IgE titers, we first analyzed 80 patients with mold allergy for Pen c
13-binding IgE by ELISA. The sera from 10 patients displaying
high IgE reactivity were used to identify potential B-cell epitopes in
Pen c 13.The distribution of Pen c 13-specific IgE values in all
Table 2. Characteristics of peptide fragments used for human IgE-binding dot-blot assays.
Peptide No. IgE reactivity (%) N-terminal sequence Mass (Da) [M+H]
+ Position in Pen c 13
S1 10 ANVVQ 2013.0 Ala
1-Lys
19
S2 – TGTTS 1008.4 Thr
21-Asp
29
S3 – TYDST 1336.5 Thr
27-Tyr
39
S4 70 STAGE 2154.0 Ser
30-Asp
51
S5 10 GVDTG 1362.6 Gly
40-Phe
52
S6 – FGGRA 1406.4 Phe
52-Asp
64
S7 10 WGTNV 2814.0 Trp
58-Lys
85
S8 10 YGVAK 537.4 Tyr
86-Lys
90
S9 – KATLV 829.0 Lys
91-Lys
98
S10 60 VAVKV 2220 Val
95-Trp
117
S11 50 VLGAD 2121 Val
99-Lys
120
S12 20 AKSRG 1970 Ala
122-Glu
140
S13 – YVMNM 1462.0 Tyr
131-Lys
143
S14 – SKAVN 1691.0 Ser
142-Phe
158
S15 – AVNDA 1071.0 Ala
144-Lys
154
S16 90 AAANV 1818.0 Ala
148-Glu
166
S17 – NASNS 1105.1 Asn
169-Glu
180
S18 50 VCTIA 2442.0 Val
181-Asp
204
S19 60 TNFGS 2771.0 Thr
197-Leu
224
S20 – SGTSM 1489.0 Ser
225-Tyr
240
S21 – AAPHV 1222.2 Ala
230-Met
242
S22 100 ALEGV 3438.0 Ala
243-Lys
274
S23 – IVQLA 1174.0 Ile
256-Arg
266
S24 – LLYNG 905.5 Leu
275-Val
282
The purity of the peptides was assessed by N-terminal sequencing.
N-terminal residues were determined by Edman degradation.
Mass was determined using a QSTAR XL mass spectrometer.
doi:10.1371/journal.pone.0034627.t002
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allergic patients showed IgE binding to rPen c 13 at levels
exceeding the two-fold mean of controls. Some characteristics of
10 patients selected for further evaluation and associated serum
total IgE levels are shown in Table 1.
Identification of IgE-binding epitopes of rPen c 13
Peptide fractions corresponding to 24 peptides covering almost
the entire amino acid sequence of Pen c 13 were produced by
cleavage for use in dot-blot screens of sera from 10 Pen c 13-
allergic individuals (A–J) (Fig. 2). The intensity of IgE binding and
epitope recognition by serum IgE varied substantially among
individuals. Twelve different IgE-binding determinants were found
among the 24 peptides. Antibody-binding regions were identified
in peptides S1, S4, S5, S7, S8, S10, S11, S12, S16, S18, S19 and
S22, corresponding to residues 1–19, 30–51, 40–52, 58–85, 86–90,
95–117, 99–120, 122–140, 148–166, 181–204, 197–224 and 243–
274, respectively. Table 2 summarizes the IgE reactivity of these
12 IgE-binding epitopes and their respective positions in the Pen c
13 molecule. Epitopes S16 and S22 were recognized by serum IgE
from 90% (9/10) and 100% (10/10) of the mold-allergic patients,
and both epitopes were classified as dominant epitopes in the
sampled population. Other epitopes were recognized by serum
IgE in 10–70% of the 10 patients tested. The control serum sample
(K) showed no IgE reactivity (Fig. 2).
Confirmation of the major IgE-binding epitopes by
inhibition ELISA
To analyze the relevance of IgE-binding sequences identified by
dot-blotting, we performed IgE ELISA inhibition experiments.
Three serum samples that recognized the epitopes S16 and S22 of
Pen c 13 in dot-blots were used for ELISA inhibition analysis. Sera
from patients preincubated with different concentrations of the
peptide (S16, S22 or S16+S22) were evaluated for IgE binding to
rPen c 13. The results showed that IgE reactivity with Pen c 13
was inhibited in a concentration-dependent manner by epitope
S16 and/or S22 (Fig. 3A–C). For inhibition control, using Pen c
13 as a positive control and albumin as a negative one with a pool
of sera were carried out to compare the inhibition capacity. As
shown in Fig. 3D, maximal inhibition reaching 69.15% was found
at 3 mM concentration of rPen c 13. Taken together, these results
demonstrate that S16 and S22 are the major epitopes of Pen c 13.
Figure 3. ELISA inhibition of S16 and S22 with sera from Pen c 13-allergic patients. A–C, Sera from three Pen c 13-reactive patients (1:10
dilution) were pre-incubated with different concentrations of purified S16 (N), S22 (#), or S16 and S22 (.) overnight at 4uC. The pre-incubated
serum samples were transferred to rPen c 13-coated wells, and bound IgE was analyzed by ELISA. The percentage of binding inhibition after pre-
incubation with the different inhibitors was calculated as [(OD2OD inhibitor)/OD]6100, where OD (optical density) and OD inhibitor indicate the
absorbance values obtained without and with inhibitors before incubation, respectively. Samples were analyzed in triplicate. Error bars indicate the
standard deviations of the measurements. D, Various concentrations of either rPen c 13 or albumin were pre-incubated with a pool of serum from 10
Pen c 13-reactive patients.
doi:10.1371/journal.pone.0034627.g003
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epitopes in Pen c 13
According to the results of IEDB prediction, shown in Table 3,
the most critical residues involved in IgE binding are located in the
C-terminus of the S22 peptide, especially the final six-residue
region, which had higher prediction scores. To obtain more
detailed information on the binding of IgE to Pen c 13, we built a
3D structure of Pen c 13 using the crystal structure of the cuticle-
degrading protease, Ver112, secreted by Lecanicillium psalliotae,a sa
suitable template (PDB ID: 3F7M). The identity and similarity
between the target and template were 48% and 67%, respectively.
As shown in Figure 4A, the model consists of an a/b core flanked
by several amphipathic helices and anti-parallel b sheets. IgE
reactivities is depicted by colors based on their intensity as follows:
negative (blue), weak (green), intermediate (yellow), and strong
(red). Epitope S1 is situated on the N-terminal b-sheet, one turn,
and an a-helix, whereas S18 and S19 are located on one turn and
four b-sheets close to the C-terminus. Epitope S4 consists of two
turns and one b-sheet adjacent to the N-terminal region, whereas
S5, situated similarly, lacks one turn and part of the b-sheet,
accounting for its marked reduction in IgE reactivity. Epitopes S7
and S8 consist of two turns and one a-helix. Epitopes S10, S11,
and S12 consist of three turns, two b-sheets, and one a-helix;
epitope S10/S11 is considered to contain the same allergenic sites
(one turn and one helix), but S10 contains an extra b-sheet in its N
terminus. Of the two immunodominant IgE epitopes, S16 forms
a-helices and a b-sheet in the middle part of the protein, and S22
forms a-helices and turns in the extreme C-terminal domain. The
current model of Pen c 13 reveals that the six residues predicted
from IEDB are situated on a turn and are located on the protein
surface (Fig. 4B). Thus, we suggest that the final six-residue region
is an important antigenic region of Pen c 13.
Modulation of IgE reactivity by site-directed mutagenesis
To validate the IgE-binding region of Pen c 13 (A
243–K
274) and
narrow down the candidate epitope residues predicted by the in
silico-based method, we expressed and isolated the GST fusion
peptides, rPen c 13 (A
243–A
260) and rPen c 13 (T
261–K
274).
Immunoblotting unambiguously showed that IgE reactivity is
located in the rPen c 13 (T
261–K
274) (Fig. 5A), consistent with in
silico predictions. Using site-directed mutagenesis assays, we
further confirmed the theoretical prediction of potential IgE-
binding regions, which presumably exhibit both a protuberant
local surface and an electrostatically active local molecular
domain. Consistent with this presumption, the side chains of
Figure 4. Molecular models and the immunodominant IgE-binding epitope of Pen c 13. A, Surface and ribbon diagrams of the Pen c 13
model. The different strengths of IgE-binding epitopes are colored green (weak), yellow (intermediate), and red (strong). Different levels of IgE-
binding intensity are defined as: weak (10–20%), intermediate (50–70%), and strong (90–100%). B, Stick diagram of Pen c 13 residues 269–274.
doi:10.1371/journal.pone.0034627.g004
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surface, as shown in Figure 4B. We therefore created the alanine
(A) substitution mutants, S269A, G270A, T271A, T272A, S273A
and K274A, corresponding to these six residues within the rPen c
13 (T
261–K
274) GST fusion, and assayed their ability to bind IgE.
The result of the immunoblot strip in patient 10 was shown in
Fig. 5A. The bands were quantified by densitometric analysis and
shown as histogram (Fig. 5B). Of the six individual substitutions,
the K274A mutation fully abolished IgE recognition; in contrast,
the G270A mutation substantially increased IgE-binding capacity.
In addition, pooled serum IgE from 10 patients was analyzed in
the same manner, and the critical amino acids for IgE-binding
were found to be the same as in patient 10 (data not shown). These
results suggest that G270 and K274 are important for the IgE-
binding activity of the Pen c 13 allergen. In order to validate the
reduced IgE reactivity, we performed dot-blot immunoassay using
two synthetic peptides (TSSISRAPSGTTSK and TSSIS-
RAPSGTTSA), followed by probing with pool serum from 10
patients. The result is shown in Fig. 5C; no binding of the serum
IgE was observed when the alanine was substituted at the lysine
position.
Discussion
Identification of IgE-binding epitopes might provide a better
understanding of the functional role that allergens play in the
disease and could have implications for immunodiagnosis and
immunotherapy. A number of approaches are currently used to
predict linear epitopes, including sequence-based prediction
Table 3. BepiPred Linear Epitope Prediction scores of each
residue in the S22 peptide (residues 243–274 of Pen c 13).
Position Residue Score Position Residue Score
1 A
243 20.092 17 L
259 20.487
2 L
244 0.21 18 A
260 20.582
3 E
245 0.25 19 T
261 20.222
4 G
246 0.444 20 S
262 0.155
5 V
247 0.531 21 S
263 0.309
6 S
248 0.568 22 I
264 0.757
7 A
249 0.734 23 S
265 1.057
8 G
250 0.511 24 R
266 1.263
9 N
251 0.331 25 A
267 1.336
10 A
252 0.106 26 P
268 1.397
11 C
253 20.321 27 S
269 1.758
12 A
254 20.388 28 G
270 1.789
13 R
255 20.85 29 T
271 1.855
14 I
256 20.979 30 T
272 1.938
15 V
257 20.896 31 S
273 1.981
16 Q
258 20.728 32 K
274 1.824
doi:10.1371/journal.pone.0034627.t003
Figure 5. Analysis of IgE reactivity to GST fusion peptides and synthetic peptides. A, The data shown represent the results for patient 10.
Immunoblots of purified GST fusion peptides Pen c 13 (A
243–K
274), (A
243–A
260) and (T
261–K
274); GST fusion Pen c 13 (T
261–K
274) mutant peptides S269A,
G270A, T271A, T272A, S273A or K274A; and GST only, probed with serum from a Pen c 13-allergic patient. The protein blots were stained with Fast
Green as a loading control. B, The histogram shows the quantitative densitometry of the bands. C, The critical amino acid for IgE-binding in Pen c 13
(T
261–K
274) was validated further using two synthetic peptides and tested for IgE-binding reactivity with pool serum from 10 allergic patients. The
sequences of two synthetic peptides are listed, and the residue that was changed to alanine is underlined. Alanine substitution is shown in boldface
letter.
doi:10.1371/journal.pone.0034627.g005
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es, most of which are based on the physicochemical properties of
the amino acids in the molecule, may provide a better
understanding of antigen-antibody binding. Linear epitopes of
antigens share some common properties: they are exposed to the
surface of the allergenic molecule, making them easily accessible;
they are localized to flexible regions; and they are composed of
polar residues.
In the present study, we mapped IgE-binding epitopes using
enzymatically/chemically cleaved fragments to obtain more
detailed information on the binding of IgE to the Pen c 13
molecule. Cleaved peptides covering most of the sequence of Pen c
13 were analyzed by dot-blotting using sera from mold-allergic
patients. Twelve distinct IgE-binding epitopes distributed through-
out the entire molecule were found, although additional epitopes
may also exist. Only a few epitopes may have been missed because
epitopes are located on cleavage sites and small gaps in the
sequence coverage. In molecular modeling studies, these regions
were predicted to lie on the protein surface and contained mostly
solvent-exposed residues. The results suggest that IgE predomi-
nantly recognizes linear epitopes, the S22 peptide (residues 243–
274), accounts for a high percentage of Pen c 13-specific IgE
binding. In a 3D model of Pen c 13 based on the structure of
Lecanicillium psalliotae Ver112, the IgE-binding determinant
261TSSISRAPSGTTSK
274 assumes a loop-like structure on the
surface of the protein. This finding is consistent with the known
importance of loop-like structures in IgE binding and the reported
allergenicity of other allergens, such as transaldolase, a fungal
allergen whose IgE-reacting fragment is located in a loop-like
structure of the C-terminal region [47]; the dust mite allergen Der
f 7, whose IgE-binding epitope forms a loop-like structure on the
surface of the protein [48]; the olive pollen allergen Ole e 9, whose
B-cell epitopes within the C-terminal domain are mainly located in
loops [49]; the mugwort pollen allergen Art v 1, whose non-linear
IgE epitopes are found within exposed loop regions harboring
lysine residues [50]; and the bovine milk allergen b-lactoglobulin,
whose strongest IgE epitope is located in a loop [51]. Furthermore,
IgE interactions with hyaluronidase, a major bee venom allergen,
may also involve a surface-exposed loop-like IgE determinant [52].
Using computational prediction, we further narrowed the
responsible sequence to a six-residues region (
269SGTTSK
274)
and generated six mutants with single alanine substitutions to test
the role of the predicted residues. The K274A mutation largely
abolished IgE-binding ability, reflecting charge and/or size
differences between lysine and alanine, implying that K274 is a
major contributor to this interaction. Dramatic effects of single
amino acid substitutions on the IgE-binding properties of allergens
have been previously reported [34,48,53–56]. Findings from these
studies suggest the importance of surface charged residues in the
IgE binding and allergenicity of an allergen. For instance, it was
found that the IgE-binding epitopes of the dust mite allergen Der f
13 [54], the latex allergen Hev b 6.02 [53], and the cockroach
allergen Bla g 2 [56] are confined to lysine residues exposed on the
surface of the allergens, a result similar to our observations for Pen
c 13.
IgE antibodies in sera of allergic subjects are considered to be
polyclonal and may recognize several different epitopes on an
allergen. We modeled the K274A and G 270A mutant structures
and then compared to the native structure, which shows no
difference in the entire molecule. In fact, a previous study
indicated that mutation of single epitope within whole allergen had
little influence on IgE binding, but a combination of several
mutated epitopes in the entire molecule was able to reduce IgE
reactivity dramatically [57]. Moreover, in an animal model
intranasal application of genetically produced hypoallergenic
fragments of Bet v 1 produced mucosal tolerance that was seen
with the complete Bet v 1 allergen [58]. Clinical studies using short
peptides may have an advantage of being unable to activate mast
cell and basophil by cross-link allergen-specific IgE while
maintaining their ability to modify T-cell and/or B-cell responses
resulting in reduction in Th2 cytokines and late phase reaction on
challenge [59–62]. Based on the above studies, we conclude that
the K274A mutant of Pen c 13 with abolished IgE-binding activity
may be a candidate for immunotherapy of mold allergies.
Genetically modified recombinant allergen derivatives designed
to reduce allergenic activity induce blocking antibodies that inhibit
the binding of allergic patients’ IgE antibodies to allergens and
hence represent a B cell-based approach to the treatment of
allergies [63,64]. Moreover, these molecules may also preserve the
repertoire of allergen-specific T cell epitopes, and thus can be
utilized for targeting T cells. The use of peptide fragments
corresponding to T-cell epitopes to induce immunologic tolerance
has been reported in experimental models of allergic disease
[61,65–68]. Our approach is based on a clear rationale and
measurable parameters for the development of recombinant
hypoallergen derivatives. However, T cell epitope within S22
peptide still remains to be elucidated by in vitro and in vivo assay.
In conclusion, we characterized a dominant linear IgE epitope
of Pen c 13 in this study, identifying residues 261–274 as an
immunodominant epitope. Gly270 and Lys274 are among the
critical core amino acids of Pen c 13 recognized by human IgE
antibodies. These residues are located on a loop-like structure at or
near the surface of Pen c 13. The results obtained from the present
study provide information on the molecular and structural features
that define the allergenicity of the Pen c 13 allergen and can be
used for developing better diagnostic tools and effective immuno-
therapeutic strategies for the clinical management of fungal
allergy.
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